815 related articles for article (PubMed ID: 25807214)
1. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K
Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214
[TBL] [Abstract][Full Text] [Related]
2. Anti-interleukin-17 treatment of psoriasis.
Jinna S; Strober B
J Dermatolog Treat; 2016 Aug; 27(4):311-5. PubMed ID: 26943806
[TBL] [Abstract][Full Text] [Related]
3. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
[TBL] [Abstract][Full Text] [Related]
4. IL-17 inhibitors for psoriasis.
Paek SY; Frieder J; Kivelevitch D; Menter MA
Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
[TBL] [Abstract][Full Text] [Related]
5. Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
Canavan TN; Elmets CA; Cantrell WL; Evans JM; Elewski BE
Am J Clin Dermatol; 2016 Feb; 17(1):33-47. PubMed ID: 26649440
[TBL] [Abstract][Full Text] [Related]
6. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
Tausend W; Downing C; Tyring S
J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
[TBL] [Abstract][Full Text] [Related]
7. Anti-IL17 therapies for psoriasis.
Silfvast-Kaiser A; Paek SY; Menter A
Expert Opin Biol Ther; 2019 Jan; 19(1):45-54. PubMed ID: 30500317
[TBL] [Abstract][Full Text] [Related]
8. Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy.
Roman M; Chiu MW
Drug Des Devel Ther; 2017; 11():2065-2075. PubMed ID: 28744098
[TBL] [Abstract][Full Text] [Related]
9. Psoriasis: rationale for targeting interleukin-17.
Girolomoni G; Mrowietz U; Paul C
Br J Dermatol; 2012 Oct; 167(4):717-24. PubMed ID: 22716185
[TBL] [Abstract][Full Text] [Related]
10. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis.
Chiricozzi A
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():9-20. PubMed ID: 25398488
[TBL] [Abstract][Full Text] [Related]
11. Anti-IL-17 Agents for Psoriasis: A Review of Phase III Data.
Farahnik B; Beroukhim K; Nakamura M; Abrouk M; Zhu TH; Singh R; Lee K; Bhutani T; Koo J
J Drugs Dermatol; 2016 Mar; 15(3):311-6. PubMed ID: 26954316
[TBL] [Abstract][Full Text] [Related]
12. No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents.
Chiricozzi A; Romanelli M; Saraceno R; Torres T
Expert Opin Drug Saf; 2016 Dec; 15(12):1653-1659. PubMed ID: 27554637
[TBL] [Abstract][Full Text] [Related]
13. A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies.
Campa M; Menter A
Expert Opin Investig Drugs; 2016 Nov; 25(11):1337-1344. PubMed ID: 27687859
[TBL] [Abstract][Full Text] [Related]
14. Anti IL-17 in psoriasis.
Ly K; Smith MP; Thibodeaux Q; Reddy V; Liao W; Bhutani T
Expert Rev Clin Immunol; 2019 Nov; 15(11):1185-1194. PubMed ID: 31603358
[No Abstract] [Full Text] [Related]
15. IL-17 for therapy.
Kurschus FC; Moos S
J Dermatol Sci; 2017 Sep; 87(3):221-227. PubMed ID: 28633806
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease.
Hohenberger M; Cardwell LA; Oussedik E; Feldman SR
J Dermatolog Treat; 2018 Feb; 29(1):13-18. PubMed ID: 28521565
[TBL] [Abstract][Full Text] [Related]
17. Next-generation biologics in the management of plaque psoriasis: a literature review of IL-17 inhibition.
Yamauchi PS; Bagel J
J Drugs Dermatol; 2015 Mar; 14(3):244-53. PubMed ID: 25738846
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies.
Georgakopoulos JR; Phung M; Ighani A; Yeung J
J Am Acad Dermatol; 2018 Jul; 79(1):155-157. PubMed ID: 29307635
[No Abstract] [Full Text] [Related]
20. Review of IL-17 inhibitors for psoriasis.
Amin M; Darji K; No DJ; Bhutani T; Wu JJ
J Dermatolog Treat; 2018 Jun; 29(4):347-352. PubMed ID: 29058501
[No Abstract] [Full Text] [Related]
[Next] [New Search]
